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Background: In the context of growing health concerns over antibiotic resistance, the evaluation of the minimum
inhibitory concentration (MIC) of vancomycin for Streptococcus pneumoniae (S. pneumoniae) strains resistant to
ceftazidime becomes important for guiding health policy makers. The aim of this study was to determine
vancomycin MIC of ceftazidime resistant S. pneumoniae strains.
Methods: Fifty identified serotypes of ceftazidime resistant S. pneumoniae strains were included in the study. The
vancomycin MIC of the above mentioned bacteria was determined based on the 0.5 McFarland standards, by using
a microdilution broth and the Etest method.
Results: The results showed that out of 50 ceftazidime resistant strains of S. pneumoniae, 46 strains (92%) have
shown a vancomycin MIC ≤0.19 − 0.1.5 μg/ml and only four strains (8%) have shown a vancomycin MIC equal to
1.5 μg/ml and the related maximum zone of inhibition was of 10 millimeter diameters.
Conclusions: The results of this investigation point out the emergence of S. pneumoniae strains with a vancomycin
MIC ≥1.5 μg/ml, which were resistant to ceftazidime. This finding uncovers a major health concern: a vancomycin
MIC higher than 1.5 μg/ml and maximum zone of inhibition of only 10 millimeter. These findings represent an
important warning for health authorities globally, concerning the treatment of patients, as the occurrence of
S. pneumoniae strains with decreased vancomycin susceptibility has been demonstrated.
Keywords: Ceftazimdime resistance, Etest, Streptococcus pneumoniae, Vancomycin, Minimum inhibitory
concentration, Maximum zone of inhibitionBackground
Streptococcus pneumoniae (S. pneumoniae) is one of the
major causes of invasive bacterial disease, such as pneu-
monia and meningitis, leading to increased morbidity and
mortality rates, especially among the elderly and infants
[1]. In addition, the results of a recent study have showed
that S. pneumoniae is colonizing the nasopharynx and, on
a single occasion, appropriate culturing yields pneumo-
cocci in 5 − 10% of healthy adults and 20 − 40% of healthy
children. With regard to healthy carriers, children are at a* Correspondence: Mehrab@bmsu.ac.ir
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unless otherwise stated.higher mortality risk compared to elderly and also, have
an increased risk of pneumococcal infection. It has been
shown that by repeated attempts and with the improve-
ment of bacteriological methods, the percentage of naso-
pharyngeal carriers rises from 40% to 60%, or greater, in
all age groups [2]. This finding may be an explanation of
the development of antibiotic-resistant strains. Because
penicillin is the first drug of choice in the treatment of
pneumococcal infections, yet the incidence of penicillin
resistance in S. pneumoniae has increased dramatically,
this phenomenon becomes a major health concern world-
wide [3,4]. Results of a previous study have revealed that
penicillin resistance rate was 65% in children, versus 22%
in adults [5]. Furthermore, the increase of multidrug re-
sistance in S. pneumoniae isolates makes the treatment oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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mycin is the last drug of choice in the case of pneumococ-
cal meningitis caused by non- susceptible to penicillin
strains and it has been used more frequently for severe,
invasive infectious disease, where resistance to other
antibiotics was present. This translates into the fact that
vancomycin plays a key role in the management of
multidrug-resistant pneumococcal infections [7]. These
data emphasized antibiotic susceptibility surveillance
systems are an important tool for preventing the emer-
gence and spread of multidrug-resistant pathogens.
Only limited data available suggest that imipenem and
vancomycin may be the most active against penicillin-
resistant strains of S. pneumoniae [8,9]. However, the
results of another study, in Serbia, indicated that multi-
drug resistance was found in one third of pneumococcal
isolates, whereas all isolated pneumococcal strains were
susceptible to vancomycin, linezolid, fluoroquinolones, tel-
ithromycin and rifampicin [1]. Nevertheless, vancomycin
tolerant S. pneumoniae strains have been reported and
characterized [10]. In order to determine vancomycin tol-
erance (VTSP) or vancomycin non susceptible of S. pneu-
moniae, continuous and comprehensive monitoring of
minimum inhibitory concentration (MIC) may be success-
fully associated with the management and treatment [11].
Recently, based on research results, the ability to survive
exposure to an antibiotic, through the loss of autolysin ac-
tivity or triggering, is termed “tolerance” [12,13]. As a re-
sult, Normark BH and his colleagues showed the limiting
criteria for pneumococcal vancomycin tolerance. They
showed that the mean log kill value was three (SD ± 0.3)
and the mean loss of optical density (OD) was 89% (SD ±
3). The results of these investigators’ studies indicate that,
for the pneumococcal lyt 4–4 strain, the log kill was 1.4
(SD ± 0.3) and the loss of OD was 19% (SD ± 12). Based
on these limitations, they have defined vancomycin toler-
ance as a log kill of ≤2 and as OD loss of ≤43% [14]. As
can be seen, the interpretation of data on vancomycin tol-
erance is very difficult and may be impossible for clinical
laboratory technicians. However, recent data show that
the MIC of the antibiotic has changed and it has been sug-
gested that this tolerance could result in the development
of drug resistance [15]. The initial therapy for S. pneumo-
niae infections based on accurate antibiotic resistance pat-
terns among isolates in every region becomes a necessity
and leads to a minimization of the development of anti-
biotic resistance [16]. The results of a previous study of
our team revealed that 48% of S. pneumoniae strains were
resistant to ceftazidime [17]. Therefore, specific and re-
liable studies are needed to detect and evaluate the
vancomycin MIC among ceftazidime resistant pneumo-
coccal clinical isolates in Iran. Therefore, the aim of this
study was to determine vancomycin MICs, with the distri-
bution of ceftazidime resistant S. pneumoniae serotypes inIranian patients, by using serial microdilution and the
Etest method.
Materials and Methods
In this investigation, vancomycin MIC strips (MIC Test
Strip, Liofilchem, Roseto degli Abruzzi Italy) were used.
Serial microdilutions of native manufactured vanco-
mycin (500 mg/vial, Dana Pharmacological Co, Tabriz,
Iran) were performed, while Mueller-Hinton broth
(Merck, Darmstadt, Germany), defibrinated lysed sheep
blood (Baharafshan Co., Teheran, Iran), 96-well micro-
plate (Technogen Spa, Pontenure Piacenza, Italy) and
injectable distilled water were used.
Bacterial strains
A total of 50 clinical S. pneumoniae strains, with previ-
ously determined serotypes [1] and also resistant to ceftaz-
idime, were subjected to vancomycin MIC determination.
By using standard procedures recommended, lyophilized
strains were recovered. In this investigation, antimicrobial
susceptibility testing was performed according to Clinical
and Laboratory Standards Institute (CLSI) guidelines [18].
The antimicrobial susceptibility patterns of the strains to
vancomycin were determined by using both microdilution
and the Etest method as confirmatory testing.
Inoculums size
Bacterial suspensions for inocula were prepared from
18 hours BHI broth medium equivalent to McFarland 0.5
standard, which provides turbidity comparable with that
of a bacterial suspension containing 1.5 × 108 colony-
forming units (CFU)/ml. In fact, a McFarland 0.5 standard
corresponds to an OD 600 between 0.08 and 0.1.
Vancomycin minimum inhibitory concentration
determination by etest method
Each of the bacterial strains were separately inoculated
on Muller-Hinton Agar plate (MHAP) containing 5%
defibrinated lysed sheep blood and a vancomycin MIC
test strip (Liofilchem, Roseto degli Abruzzi, Italy) was
placed on the inoculums lawn. Briefly, the procedure
was performed as follows: a sterile swab was sunk into
the bacterial suspension and then inocula onto Muller-
Hinton 5% defibrinated sheep blood agar plates and after
15 to 20 min, when the bacterial suspension were absorbed
onto the medium, vancomycin MIC strips were applied on
the plate. The plates were incubated at 37°C for 24 h in an
atmosphere containing 3− 5% CO2.
After the incubation period, the elliptical zone of inhib-
ition was measured and the MIC of each strain was deter-
mined, separately. The MIC was the point where the
elliptical zone of growth inhibition intersected the MIC
scale on the vancomycin strip. The antibiotic gradient
scale on the vancomycin MIC strip was 0.016 − 256 μg/ml.
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determination by serial microdilutions method
Based on our previous reports and references of bacterial
strains applied [19], the stock solution of vancomycin was
prepared. Serial concentrations with twice the anterior
value progressive rate (0.5, 1, 2, 4, 8, 16, 32, 64, 128 μg/well)
of vancomycin were then prepared and loaded into defined
rows of 96 well microplates from the antibiotic stock solu-
tion. Plates were incubated at 35°C for 24 hours, until evap-
oration and finalization of the process of loading the
antibiotic into the plate. The plates were stored in a re-
frigerator at 4°C for 3 hours.
The designing of the 96-well microplate (for prepar-
ation of the serial dilutions of vancomycin) was per-
formed as follows: one row for negative control, one row
for positive control and three rows for tests were
marked, respectively. Therefore, each 96-well microplate
was considered to measure the antibiotic sensitivity of
two bacterial strains. The negative control rows for each
case consisted of the serial dilutions of vancomycin (0.5, 1,
2, 4, 8, 16, 32, 64, 128 μg/well), culture media (Mueller-
Hinton broth containing 3% defibrinated sheep blood) and
no bacterial suspension. The positive control rows con-
sisted of culture media (Mueller-Hinton broth containing
3% defibrinated sheep blood) and the bacterial suspension.
The positive control rows were lacking vancomycin. The
three rows of microplates for tests with equal conditions
were used for each bacterial strain testing. The test rows
were composed of serial dilutions of vancomycin (0.5, 1, 2,
4, 8, 16, 32, 64, 128 μg/wells, respectively), culture media
and bacterial suspension. After inoculation and incuba-
tion, the plates were subjected to scanning at 450 nm of
wavelength ELISA reader. Data were analyzed using unilat-
eral analysis of variance (ANOVA). In our statistical ana-
lyses, α =0.05 was considered acceptable for significant
variation and the results were analyzed using SPSS Version
16.0 Software (SPSS Inc., Chicago, IL, The USA).
Molecular assay for resistance gene
In this study, we used previously published collections of
primer pairs [20] or designed them based on the nucleo-
tide reference GeneBank. Polymerase chain reactions
(PCR) for PBP2b, PBP2x, gyrA, vex2 and vncS genes,
which amplified 1500, 1920, 2100, 400 and 1000 bp frag-
ments were performed respectively (Table 1).
In our study, the mentioned primer pairs were selected
and synthesized by CinnaGen Co, Teheran, Iran. For the
detection and amplification of the above mentioned
genes, overnight grown bacterial cells of the late expo-
nential phase were subjected to DNA extraction, using
the salting out method [21]. The 25 μL volume PCR re-
action master mixes were prepared in 0.2 mL microcen-
trifuge tubes. An individual reaction was carried out as
follows: 2.5 μL PCR buffer (10x), MgCl2 (50–150 mMgradient), 0.5 μL dNTPs (10 mM), 0.5 μL of each primer
(100 pm/μl), 0.5 μL Taq DNA polymerase (5 unit/μl),
1.5 μL template DNA and 18.5 μL sterile deionized
water. All the materials used in PCR reactions were pur-
chased from CinnaGen Co., Teheran, Iran. Thermal cyc-
ling was performed in the Analytic Jena PCR system
(Analytic Jena AG, Jena, Germany). The PCR process in-
cluded denaturalization at 94°C for 6 min, followed by 35
amplification cycles of 94°C for 45 s, 61°C for 30 s, 72°C
for 1 min and with 5 min final extension at 72°C. For the
analysis of the PCR products, 1.5% agarose gel containing
1X TBE buffer was prepared and was run at 100 V for
40 min. For determining the size of the PCR products, we
have used a 50 bp DNA ladder.
Results
Demographic analysis revealed that the mean age of pa-
tients participating in this study was 52 years old (16 to
73 years old), of which 30 (60%) were women and 20
(40%) were men.
The results of vancomycin susceptibility pattern
The results of broth microdilution method with vanco-
mycin gradient (concentration) ranges of 0.5, 1, 2, 4, 8,
16, 32, 64, 128 μg/well revealed that 46 isolates (92%)
with MIC ≤1.5 μg/well were obtained. Four strains (8%)
with MIC ≥1.5 μg/well, one of them with a MIC =8 μg/well
(Figure 1), were detected. The results of vancomycin MIC
determined by the Etest and broth microdilution method
for these strains were the same. In fact, the comparative
results of broth microdilution and Etest method revealed
46 isolates (92%) with a MIC ≤1.5 μg/ml, three strains
(6%) with MIC ≥1.5 ≤ 6 μg/ml and one strain (2%) with
MIC 8 μg/ml. However, analysis of the Etest results indi-
cated that the lowest MIC, was 0.125 μg/ml, belonged to
serotype 4, followed by serotypes 6 and 5, which were iso-
lated from different wounds, while three strains from the
lungs, with a MIC =0.25 − 0.75 μg/ml and one strain with a
MIC =0.38 μg/ml, isolated from the blood, belonged to
serotype 1 (Table 2).
Figure 1 shows the example of a 24 hours incubation
period of a 96-well microplate used for measuring the
antibiotic sensitivity of two bacterial strains. The results
of the subculturing of each well showed that the vanco-
mycin MIC for S. pneumoniae strains was the same as of
the Etest strip results, which are displayed in Table 2.
The unilateral ANOVA of the OD of each well at time 0
and 24 hours after incubation of the bacterium with dif-
ferent concentrations of antibiotics per well have shown
the significant differences (P ≤0.02).
The results of this study revealed that the vancomycin
MIC of 92% of pathogenic S. pneumoniae is 0.19 −
1.5 μg/ml, as a vancomycin susceptible strain, while 8%
of them have a vancomycin MIC ≥1.5 μg/ml, being
Table 1 The sequences of the primer pairs used in this study
Gene Nucleotide sequences Charactristics
Size of amplified product (bp) Induce resistant to Reference
PBP2b F – 5′ GAT CCT CTA AAT GAT TCT CAG GTG G 3′ 1500 bp Penicillin [20]
R – 5′ TGG TGT TCG TGT GGC TCC TC 3
PBP2x F- 5′ GAT TGC TGA GGA TGC AAC CTC TTA TAA TGT CTA TG 3′ 1920 bp Ceftazidime
R −5′ GCC TTG AAA TTC AAG TTC TAT ATT GAG CCA CTT AGC 3′ Ceftriaxon
gyrA F – 5′ CCG TTG TGA AAG TCA CTA TCT G 3′ 2100 bp Ciprofloxacin In this study
R – 5′ AGT TGC TCC ATT AAC CA 3′
vncS F – 5′ AAA CAA TTG ACC TCC TCC AGA TG 3′ 1000 bp Vancomycin
R – 5′ TTC TAA CTC CAT CTA TGT AAA CC 3′
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or tolerant, which belonged to serotype 17 and was iso-
lated from the blood.
The results of the susceptibility pattern obtained in
this study have shown that the most frequent S. pneu-
moniae strain with sensitivity to vancomycin was sero-
type 6, isolated from lung. In Figure 2, rows A − C
showed the three Ceftazidime resistant S. pneumoniae
strains with MICs of 6, 12 and 32 μg/ml, respectively, while
part D and E showed the two S. pneumoniae strains with
decreased vancomycin sensitivity, with a MIC ≥1.5 μg/ml.
The key finding of this study is shown in the last col-
umn of Table 2. By comparing the obtained growth zone
of inhibition, we can estimate the vancomycin suscepti-
bility rate or tolerance of the bacterial strains. For ex-
ample, the vancomycin MIC for S. pneumoniae serotype
4 was 0.125 μg/ml, while vancomycin MIC for serotypesFigure 1 Illustration an example of the 96 well micro plate’s broth micr
In this plate the 9 wells in A row is negative control and two three test rows (
for vancomycin MIC determination which contain the serial concentration of
well on column 11 are marked as positive control.17 and 20 were 8 and 6 μg/ml, respectively, with the
same zone of inhibition.
Results of molecular assay
The results of the molecular assay for vncS and vex2
genes revealed that the used primer pairs in this study
were not able to amplify the coding sensor histidine kin-
ase sequences as vancomycin tolerant in all 50 isolated
strains of S. pneumoniae, while the results of PCR for
PBP2b, PBP2x and gyrA, as determinants of penicillin,
ceftriaxone, ceftazidime and ciprofloxacin resistance, amp-
lified the fragment of their related genes (Figure 3). On
the other hand, the PCR protocol shows no vancomycin
tolerant genes in the studied S. pneumoniae strains.
The outlined results of this study revealed that the
vancomycin MIC of 92% (46 strains) of pathogenic S.
pneumoniae is 0.19 − 1.5 μg/ml, while 8% (four strains)odilution method for two S. pneumoniae strains vancomycin assay.
rows B, C and D for strain one and the rows F, G and H for strain two)
0.5 to 128 μg/well of vancomycin respectively. Nine wells of E row and
Table 2 Results of S. pneumoniae serotype distribution and vancomycin MIC by Etest strip and broth microdilution







Minimum inhibitory concentration ranges Maximum
zone of
inhibition
MIC ≥0.1 ≤ 1 μg/ml MIC ≥1≤ 2 μg/ml MIC ≥2 ≤ 6 μg/ml MIC ≥6 ≤ 10 μg/ml
Wounds
104 6 0.38 μg/ml 2.3 mm
105 5 0.38 μg/ml 2.1 mm
381 10 1 μg/ml 1.8 mm
Lung
201; 102; 13; 120 6 0.38 μg/ml 2.9 mm
0.50 μg/ml 1.8 mm
0.75 μg/ml 2.2 mm
1 μg/ml 1.7 mm
106; 125;777 1 0.25 μg/ml 2.3 mm
0.38 μg/ml 2 mm
0.75 μg/ml 2 mm
501 4 0.125 μg/ml 1 mm
124; 130; 83 2 0.19 μg/ml 2.1 mm
0.75 μg/ml 1.5 mm
1 μg/ml 2 mm
6; 117 7 0.5 μg/ml 2 mm
0.75 μg/ml 1.8 mm
34; 107; 48;28 8 1 μg/ml 2.2 mm
1.5 μg/ml 3 mm
1 μg/ml 2 mm
1 μg/ml 2.4 mm
202 G 1 μg/ml 2 mm
Blood
133 1 0.38 μg/ml 2.1 mm
39 2 1 μg/ml 2 mm
116 4 0.5 μg/ml 2.3 mm
131; 121 6 0.25 μg/ml 2.5 mm
0.38 μg/ml 2.5 mm
89 G 0.50 μg/ml 2 mm
126; 40 17 8 μg/ml 1 mm
1.5 μg/ml 1 mm
35 18 0.75 μg/ml 2.2 mm
Eye
101 2 0.38 μg/ml 2.5 mm
5; 996; 208; 129 6 0.38 μg/ml 2.5 mm
1 μg/ml 1 mm
1 μg/ml 2 mm
1 μg/ml 1/5 mm
502; 50; 53; 7 19 0.38 μg/ml 2.1 mm
0.5 μg/ml 2 mm
0.5 μg/ml 2.5 mm
1 μg/ml 2.5 mm
14 14 0.5 μg/ml 1.7 mm
CSF
51 8 1 μg/ml 3 mm
109; 111 20 1.5 μg/ml 2 mm
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Table 2 Results of S. pneumoniae serotype distribution and vancomycin MIC by Etest strip and broth microdilution
method, containing vancomycin gradients of 0.016–256 μg/ml and 0.5–128 μg/well respectively (Continued)
6 μg/ml 1 mm
Throat
128 7 1 μg/ml 2 mm
123 20 4 μg/ml 1 mm
103 4 0.38 μg/ml 2.4 mm
108 14 5 μg/ml 1 mm
Nostrils
778; 49 7 0.5 μg/ml 1.5 mm
0.5 μg/ml 2.5 mm
Sinus 115 20 1 μg/ml 1.7 mm
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resistant to penicillin, ceftriaxone, ceftazidime were de-
tected in several S. pneumoniae strains, which had been
marked as β-lactam resistant isolates.
Discussion
Pneumococcal resistance to antibiotics, especially to peni-
cillin, poses an increased therapeutic concern [22,23]. In
addition, vancomycin tolerant S. pneumoniae had been
observed in three clinical isolates in the early ’90s [7].
However, given the fact that the antibiotic of choice forFigure 2 Sections A − C show the elliptical zone of inhibition of three S
16 and 6 μg/ml of ceftazidime, respectively. In Part D and E, antibiotic sus
ceftazidime, ceftriaxone and ciprofloxacin are shown for two S. pneumoniae st
μg/ml respectively.treating meningeal infections caused by penicillin resistant
S. pneumoniae strains is vancomycin and also, empirical
therapy for purulent meningitis caused by head trauma or
post neurosurgery are an indication for vancomycin plus ei-
ther ceftazidime, cefepime or meropenem, researchers have
recommended the necessity to assay the efficiency of
vancomycin in treating infections caused by S. pneumoniae
[14,24]. Furthermore, although tolerances to vancomycin
were obtained based on accurate experimental studies, the
determination and interpretation of vancomycin tolerance
is laborious and may pose difficulties for medical diagnostic. pneumoniae strains around ceftazidime MIC strip, with MIC =32,
ceptibility assay plates using Etest strips for penicillin, vancomycin,
rains. Arrays in part D and E are shown the vancomycin MIC = 1.5 and 4
Figure 3 Sections A, B and C depicts the amplified 1500, 1920 and 2010bp fragments of PBP2b, PBP2x and gyrA that introduces
resistance to penicillin, ceftazidime and or ceftriaxone and ciprofloxacin.
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that the Etest and microdilution methods for determination
vancomycin MIC can be easily performed and are predict-
ive indicators for the tolerance or decrease of susceptibility
to vancomycin.
In this regards, vancomycin MIC determination for
pathogenic ceftazidime resistant S. pneumoniae strains has
not been reported up to present. The results of vanco-
mycin MIC determination of different S. pneumoniae se-
rotypes were shown in Table 2. The MIC of vancomycin
for strains belonging to serotypes 2 and 4 revealed a
maximum zone of inhibition of 21 and 10 millimeter in
diameter, respectively. These two serotypes were iso-
lated from the lung. The vancomycin MIC of 10 strains
(20% of isolates) (serotypes 1, 2, 4, 5, 6, and 19) was
equal to 0.38 μg/ml of vancomycin, with a zone of in-
hibition of 20–29 millimeters in diameter. The MIC of
14 different serotypes (28% of isolates) were equal to
0.5 − 0.75 μg/ml of vancomycin, with a zone of inhib-
ition of 15–25 millimeter in diameter. The MIC for
other 14 different serotypes (28% of isolates) was equal
to 1 μg/ml of vancomycin, corresponding to a zone of
inhibition of 10–30 millimeters in diameter. Three sero-
types (6% isolates) have MICs equal to 1.5 μg/ml, with a
zone of inhibition of 1–3 centimeters in diameter. Two
isolates (4%) of the serotype 20 had a MIC of 4 and
6 μg/ml, while the MICs of serotypes 14 and 17 (4%)
were 5 and 8 μg/ml, respectively, with a zone of inhibition
equal to 10 millimeter in diameter. According to the CLSI
guidelines, a MIC of 2 μg/ml of vancomycin, with a zone
of inhibition ≤17 millimeters should be regarded as a re-
sistant strain [18]. However, the sensitive ranges of a
vancomycin MIC is less 2 μg/ml. It can be suggested thatin this study 46 S. pneumoniae strains (92%) were vanco-
mycin susceptible, while four strains (8%) manifested a de-
creasing susceptibility to vancomycin.
A very important finding of the current study was that
the isolates presenting a decreasing susceptibility to vanco-
mycin were also resistant to ceftazidime. In addition, the re-
sults of our previous study showed that nine S. pneumoniae
strains (18%) were resistant to penicillin [19]. The results of
this study indicate that only four out of 50 ceftazidime re-
sistant of S. pneumoniae strains manifested decreased sus-
ceptibility to vancomycin.
In 2010, Moscoso et al. showed that the vancomycin tol-
erance in S. pneumoniae isolates depends on reduced en-
zyme activity of the major LytA autolysin or capsular
polysaccharide [11]. In this study, the PCR methods were
not able to determine the vanA or vanB gene, which in-
duced vancomycin resistance. Despite the present study,
Kohanteb and Sadeghi (2007) reported that vancomycin
MIC for penicillin-resistant S. pneumoniae strains in Iran
was 0.03 − 0.5 μg/ml [25]. Bokaeian et al. (2011) reported
that the vancomycin MIC of S. pneumoniae from nasopha-
ryngeal carriage among healthy adolescents in Zahedan
was 0.02 − 1 μg/ml, and concluded that all S. pneumoniae
isolates were susceptible to vancomycin [26]. However,
Sanaei DA et al., which studied the nasopharyngeal carrier
rate of S. pneumoniae in children by using the disc diffu-
sion method, showed that 1.5% of S. pneumoniae isolates
were non susceptible to vacomycin [27].
Conclusion
However, have not access to positive and negative control
strains was the main limitation of this investigation. the
results of this study revealed that 92% of pathogenic
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mycin MICs of 0.19 − 1.5 μg/ml and only 8% of them have
a vancomycin MIC of 4–8 μg/ml. Based on the data col-
lected from this research, the later serotypes had been
marked as vancomycin tolerant or may be vancomycin
non- susceptible strains. However, more ample genetic
and molecular research are needed, as these findings rep-
resent an important warning to health authorities because
the occurrence of S. pneumoniae strains with multiple re-
sistances has been shown, a situation which has never
been reported before.
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